BIIB · News · 20260807N
Litigation and Legal Risk
BIOGEN INC. · 2026-08-07 · Importance 28 · Surprise 42 · In source text
Biogen reached a preliminary settlement agreement with investors in a class-action lawsuit concerning disclosures about clinical trial data for its Alzheimer’s drug Aduhelm. The plaintiffs alleged that Biogen misrepresented or withheld data showing less favorable results for patients receiving a higher dose. Settlement terms, including the financial amount, were not disclosed in the reporting. The agreement is expected to be filed within 60 days, creating a pending legal and potential cash exposure for Biogen.
Key facts
- Biogen has reached a preliminary settlement agreement with investors who filed a class-action lawsuit alleging the company misrepresented clinical trial data for its Alzheimer's drug, Aduhelm; the terms of the settlement, including the financial amount, are not yet public but are expected to be filed within 60 days. source
- The lawsuit claimed Biogen withheld data indicating patients treated with a higher dose of Aduhelm showed less favorable results. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| liability | negative | probable | — | Biogen has reached a preliminary settlement agreement with investors who filed a class-action lawsuit alleging the company misrepresented… |